Madison Investment Holdings Inc. trimmed its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 1.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,609 shares of the medical instruments supplier’s stock after selling 322 shares during the period. Madison Investment Holdings Inc.’s holdings in Becton Dickinson and were worth $6,338,000 at the end of the most recent reporting period.
Several other hedge funds have also modified their holdings of the company. BlackRock Inc. increased its stake in Becton Dickinson and by 6.0% in the 4th quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock valued at $4,026,750,000 after purchasing an additional 1,071,288 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Becton Dickinson and by 1.4% in the 4th quarter. Bank of New York Mellon Corp now owns 2,010,236 shares of the medical instruments supplier’s stock valued at $430,312,000 after purchasing an additional 26,956 shares in the last quarter. Mawer Investment Management Ltd. increased its stake in Becton Dickinson and by 1.4% in the 3rd quarter. Mawer Investment Management Ltd. now owns 1,799,828 shares of the medical instruments supplier’s stock valued at $352,599,000 after purchasing an additional 24,761 shares in the last quarter. Findlay Park Partners LLP increased its stake in Becton Dickinson and by 2.3% in the 3rd quarter. Findlay Park Partners LLP now owns 1,765,000 shares of the medical instruments supplier’s stock valued at $345,852,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Koch Industries Inc. increased its stake in Becton Dickinson and by 45,268.7% in the 2nd quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock valued at $1,391,000 after purchasing an additional 1,395,182 shares in the last quarter. 77.50% of the stock is owned by institutional investors and hedge funds.
In other news, Director Timothy M. Ring sold 269,661 shares of the firm’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the sale, the director now owns 295,753 shares in the company, valued at $64,420,918.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.00% of the stock is owned by company insiders.
Shares of Becton Dickinson and Co (BDX) opened at $220.34 on Friday. The company has a market capitalization of $58,660.00, a price-to-earnings ratio of 88.49, a price-to-earnings-growth ratio of 1.56 and a beta of 1.12. The company has a current ratio of 1.54, a quick ratio of 0.93 and a debt-to-equity ratio of 1.04. Becton Dickinson and Co has a fifty-two week low of $175.66 and a fifty-two week high of $248.39.
Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, beating analysts’ consensus estimates of $2.41 by $0.07. The firm had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. Becton Dickinson and’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.33 EPS. equities research analysts forecast that Becton Dickinson and Co will post 10.94 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be issued a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a dividend yield of 1.36%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio (DPR) is 120.48%.
Several equities analysts recently weighed in on the company. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $260.00 price objective (up from $223.00) on shares of Becton Dickinson and in a research note on Tuesday, February 6th. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price objective for the company in a research note on Wednesday, January 3rd. Evercore ISI assumed coverage on Becton Dickinson and in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 price objective for the company. Morgan Stanley raised their price objective on Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 7th. Finally, Deutsche Bank set a $260.00 price objective on Becton Dickinson and and gave the company a “buy” rating in a research note on Friday, December 29th. Four analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $237.27.
COPYRIGHT VIOLATION WARNING: “Madison Investment Holdings Inc. Has $6.34 Million Stake in Becton Dickinson and Co (BDX)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/24/madison-investment-holdings-inc-has-6-34-million-stake-in-becton-dickinson-and-co-bdx.html.
Becton Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.